Skip to content

The Characteristics of Prepulse Inhibition in Children and Adolescents Suffering From Attention Deficit Disorder

The Characteristics of Prepulse Inhibition in Children and Adolescents Suffering From Attention Deficit Disorder: With and Without Medication.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02344784
Acronym
PPI
Enrollment
46
Registered
2015-01-26
Start date
2015-01-31
Completion date
2017-06-30
Last updated
2016-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Disorder

Keywords

ADD, ADHD, PPI

Brief summary

The purpose of this study is to show that Prepulse inhibition test of acoustic startle response is an indicator of objective diagnostic characteristics of attention deficit disorder in children and adolescents. by demonstrating that Prepulse inhibition test of acoustic startle response is impaired in children and adolescents suffering from attention deficit disorder in the relation to the normal function described in the literature. The investigators will try to prove our hypothesis by an experiment that consists of two phases: Phase I (about 25 minutes): The patient will enter the room, will be asked to sit on a chair, and will be asked to look at a computer screen showing silent video of aquarium fish, then the patient will be connected to both the Prepulse inhibition test device and the Galvanic skin response device and pass the tests. Phase II (about 25 minutes): After completion of Phase I, each participant will receive his daily regular dose of methylphenidate and after an hour and a half from taking the drug, will repeat the tests, both the Prepulse inhibition test and the Galvanic skin response test. Duration of the entire experiment is 140 minutes (two hours and twenty minutes).

Interventions

DEVICESR-HLAB EMG

Prepulse inhibition test using SR-HLAB EMG device will record the acoustic startle response for each participant: with and without Methylphenidate treatment

DRUGMethylphenidate

The regular daily dose of P.O methylphenidate of each participant will be given directly after the first prepulse inhibition test

Sponsors

Technion, Israel Institute of Technology
CollaboratorOTHER
HaEmek Medical Center, Israel
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
7 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

1. Between the ages of 7-18 2. Diagnosed with attention deficit hyperactivity disorder according to Diagnostic and statistical manual of mental disorders, fifth edition- Clinical diagnostic interview was performed. 3. Receive drug therapy with methylphenidate doses ranging from 0.3 mg / kg to 1 mg / kg. 4. The participant is treated with methylphenidate at least two months prior to the experiment.

Exclusion criteria

1. Autism. 2. Chronic neurological diseases. 3. Developmental delay. 4. Psychotic or major effective disorder (psychotic state now or in the past, schizophrenia, schizoaffective, depression, bipolar disorder) 5. Substance abuse. 6. Mental retardation. 7. Contraindicated for the treatment of methylphenidate. 8. Hearing problems. 9. Pregnancy week 20 and thereafter

Design outcomes

Primary

MeasureTime frame
Electromyography (EMG) of the right and the left Orbicularis oculi muscle will be recorded during the Prepulse inhibition testThe outcome measure will be assessed imediatly during each test and the participants will be followed for the whole duration of the experiment, an expected average of 3 hours

Secondary

MeasureTime frame
Galvanic skin response will be measured by conductivity (Mv) units during the Prepulse inhibition testThe outcome measure will be assessed imediatly during each test and the participants will be followed for the whole duration of the experiment, an expected average of 3 hours

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026